Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jan;51(1):63-75.
doi: 10.1038/s41588-018-0269-7. Epub 2018 Nov 26.

Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder

Ditte Demontis #  1   2   3 Raymond K Walters #  4   5 Joanna Martin  5   6   7 Manuel Mattheisen  1   2   3   8   9   10 Thomas D Als  1   2   3 Esben Agerbo  1   11   12 Gísli Baldursson  13 Rich Belliveau  5 Jonas Bybjerg-Grauholm  1   14 Marie Bækvad-Hansen  1   14 Felecia Cerrato  5 Kimberly Chambert  5 Claire Churchhouse  4   5   15 Ashley Dumont  5 Nicholas Eriksson  16 Michael Gandal  17   18   19   20 Jacqueline I Goldstein  4   5   15 Katrina L Grasby  21 Jakob Grove  1   2   3   22 Olafur O Gudmundsson  13   23   24 Christine S Hansen  1   14   25 Mads Engel Hauberg  1   2   3 Mads V Hollegaard  1   14 Daniel P Howrigan  4   5 Hailiang Huang  4   5 Julian B Maller  5   26 Alicia R Martin  4   5   15 Nicholas G Martin  21 Jennifer Moran  5 Jonatan Pallesen  1   2   3 Duncan S Palmer  4   5 Carsten Bøcker Pedersen  1   11   12 Marianne Giørtz Pedersen  1   11   12 Timothy Poterba  4   5   15 Jesper Buchhave Poulsen  1   14 Stephan Ripke  4   5   27 Elise B Robinson  4   28 F Kyle Satterstrom  4   5   15 Hreinn Stefansson  23 Christine Stevens  5 Patrick Turley  4   5 G Bragi Walters  23   24 Hyejung Won  17   18 Margaret J Wright  29 ADHD Working Group of the Psychiatric Genomics Consortium (PGC)Early Lifecourse & Genetic Epidemiology (EAGLE) Consortium23andMe Research TeamOle A Andreassen  30 Philip Asherson  31 Christie L Burton  32 Dorret I Boomsma  33   34 Bru Cormand  35   36   37   38 Søren Dalsgaard  11 Barbara Franke  39 Joel Gelernter  40   41 Daniel Geschwind  17   18   19 Hakon Hakonarson  42 Jan Haavik  43   44 Henry R Kranzler  45   46 Jonna Kuntsi  31 Kate Langley  7   47 Klaus-Peter Lesch  48   49   50 Christel Middeldorp  33   51   52 Andreas Reif  53 Luis Augusto Rohde  54   55 Panos Roussos  56   57   58   59 Russell Schachar  32 Pamela Sklar  56   57   58 Edmund J S Sonuga-Barke  60 Patrick F Sullivan  6   61 Anita Thapar  7 Joyce Y Tung  16 Irwin D Waldman  62 Sarah E Medland  21 Kari Stefansson  23   24 Merete Nordentoft  1   63 David M Hougaard  1   14 Thomas Werge  1   25   64 Ole Mors  1   65 Preben Bo Mortensen  1   2   11   12 Mark J Daly  4   5   15   66 Stephen V Faraone  67 Anders D Børglum  68   69   70 Benjamin M Neale  71   72   73
Collaborators, Affiliations
Meta-Analysis

Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder

Ditte Demontis et al. Nat Genet. 2019 Jan.

Abstract

Attention deficit/hyperactivity disorder (ADHD) is a highly heritable childhood behavioral disorder affecting 5% of children and 2.5% of adults. Common genetic variants contribute substantially to ADHD susceptibility, but no variants have been robustly associated with ADHD. We report a genome-wide association meta-analysis of 20,183 individuals diagnosed with ADHD and 35,191 controls that identifies variants surpassing genome-wide significance in 12 independent loci, finding important new information about the underlying biology of ADHD. Associations are enriched in evolutionarily constrained genomic regions and loss-of-function intolerant genes and around brain-expressed regulatory marks. Analyses of three replication studies: a cohort of individuals diagnosed with ADHD, a self-reported ADHD sample and a meta-analysis of quantitative measures of ADHD symptoms in the population, support these findings while highlighting study-specific differences on genetic overlap with educational attainment. Strong concordance with GWAS of quantitative population measures of ADHD symptoms supports that clinical diagnosis of ADHD is an extreme expression of continuous heritable traits.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, Genomind and Neurolifesciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Shire, Neurovance, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is principal investigator of www.adhdinadults.com.

Dr. Neale is a member of Deep Genomics Scientific Advisory Board and has received travel expenses from Illumina. He also serves as a consultant for Avanir and Trigeminal solutions.

Olafur O. Gudmundsson, G. Bragi Walters, Hreinn Stefansson and Kari Stefansson are employees of deCODE genetics/Amgen.

Nicholas Eriksson, Joyce Y Tung, and the 23andMe Research Team are employees of 23andMe, Inc., and hold stock or stock options in 23andMe.

Dr. Rohde has received honoraria, has been on the speakers' bureau/advisory board and/or has acted as a consultant for Eli-Lilly, Janssen-Cilag, Novartis, Medice and Shire in the last three years. He receives authorship royalties from Oxford Press and ArtMed. He also received travel award for taking part of 2015 WFADHD meeting from Shire. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire.

Over the last three years Dr. Sonuga-Barke has received speaker fees, consultancy, research funding and conference support from Shire Pharma and speaker fees from Janssen Cilag. He has received consultancy fees from Neurotech solutions, Aarhus University, Copenhagen University and Berhanderling, Skolerne, Copenhagen, KU Leuven. Book royalties from OUP and Jessica Kingsley. He is the editor-in-chief of the Journal of Child Psychology and Psychiatry for which his University receives financial support.

Dr. Franke has received educational speaking fees from Merz and Shire.

Dr. Schachar’s disclosures: ehave equity and advisory board, Ironshore Pharmaceuticals Advisory Board.

Dr. Reif has received a research grant from Medice, and speaker’s honorarium from Medice and Servier.

Dr. Haavik has received speaker fees from Shire, Lilly and Novartis.

Dr. Kranzler has been an advisory board member, consultant, or CME speaker for Alkermes, Indivior, and Lundbeck. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences.

Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018.

Dr Asherson received honoraria paid to King's College London by Shire, Flynn Pharma, Lilly, Janssen, Novartis and Lunbeck for research, speaker fees, education events, advisory board membership or consultancy.

Dr. Andreassen has received speaker fees from Lundbeck and Sunovion. Dr Kuntsi has received speaker’s honorarium from Medice; all funds are received by King’s College London and used for studies of ADHD.

Thomas Werge has acted as lecturer and scientific advisor to H. Lundbeck A/S

Figures

Figure 1.
Figure 1.. Manhattan plot of the results from the GWAS meta-analysis of ADHD.
The index variants in the 12 genome-wide significant loci are highlighted as a green diamond. Index variants located with a distance less than 400kb are considered as one locus. The y-axis represents –log(two-sided P-values) for association of variants with ADHD, from meta-analysis using an inverse-variance weighted fixed effects model, and a total sample size of 20,183 ADHD cases and 35,191 controls. The vertical red line represents the threshold for genome-wide significance.
Figure 2.
Figure 2.. Odds Ratio by PRS for ADHD
Odds Ratio (OR) by PRS within each decile estimated for n = 18,298 biological independent individuals in the PGC samples (red dots) and in n = 37,076 biological independent individuals in the iPSYCH sample (blue dots). PRSs in the iPSYCH sample were obtained by five leave-one-out analyses, using 4 of 5 groups as training datasets for estimation of SNP weights, while estimating Polygenic Risk Scores (PRS) for the remaining target group. Odds ratios and 95% confidence limits (error bars) were estimated using logistic regression on the continuous scores.
Figure 3.
Figure 3.. Genetic correlations of ADHD with other phenotypes
Significant genetic correlations between ADHD (results from Europena GWAS meta-analysis of 19,099 cases, 34,194 controls) and other traits reveal overlap of genetic risk factors for ADHD across several groups of traits (grouping indicated by a horizontal line): educational, psychiatric/personality, weight (and possible weight related traits), smoking behaviour/smoking-related cancer, reproductive traits and parental longevity (Sample size of the external GWASs are presented in Supplementary Table 5). In total 219 traits were tested and only traits significant after Bonferroni correction are presented in the figure. Two significant educational phenotypes are omitted due to substantial overlap with years of schooling. Genetic correlation is presented as a dot and error bars indicate 95% confidence limits.

Comment in

  • First genetic risk loci for ADHD identified.
    Ridler C. Ridler C. Nat Rev Neurol. 2019 Jan;15(1):4. doi: 10.1038/s41582-018-0117-5. Nat Rev Neurol. 2019. PMID: 30531819 No abstract available.
  • Risk loci for ADHD.
    Clyde D. Clyde D. Nat Rev Genet. 2019 Feb;20(2):69. doi: 10.1038/s41576-018-0084-0. Nat Rev Genet. 2019. PMID: 30532079 No abstract available.

Similar articles

Cited by

References

    1. Faraone SV et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 15020, doi:10.1038/nrdp.2015.20 (2015). - DOI - PubMed
    1. Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS & Simonsen M Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry 2, 702–709, doi:10.1016/S2215-0366(15)00271-0 (2015). - DOI - PubMed
    1. Chang Z, Lichtenstein P, D'Onofrio BM, Sjolander A & Larsson H Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 71, 319–325, doi:10.1001/jamapsychiatry.2013.4174 (2014). - DOI - PMC - PubMed
    1. Biederman J & Faraone SV Attention-deficit hyperactivity disorder. Lancet 366, 237–248, doi:10.1016/S0140-6736(05)66915-2 (2005). - DOI - PubMed
    1. Dalsgaard S, Nielsen HS & Simonsen M Consequences of ADHD medication use for children's outcomes. J Health Econ 37, 137–151, doi:10.1016/j.jhealeco.2014.05.005 (2014). - DOI - PubMed

Methods-only references

    1. Sudmant PH et al. An integrated map of structural variation in 2,504 human genomes. Nature 526, 75–81, doi:10.1038/nature15394 (2015). - DOI - PMC - PubMed
    1. Delaneau O, Marchini J & Zagury JF A linear complexity phasing method for thousands of genomes. Nature methods 9, 179–181, doi:10.1038/nmeth.1785 (2011). - DOI - PubMed
    1. Howie B, Marchini J & Stephens M Genotype imputation with thousands of genomes. G3 1, 457–470, doi:10.1534/g3.111.001198 (2011). - DOI - PMC - PubMed
    1. Purcell S et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics 81, 559–575, doi:10.1086/519795 (2007). - DOI - PMC - PubMed
    1. Chang CC et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7, doi:10.1186/s13742-015-0047-8 (2015). - DOI - PMC - PubMed

Publication types